Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH
← catalyst calendarNCT07335601 · readout ≤ 743 d
Sponsored by Madrigal Pharmaceuticals, Inc. (industry) · MDGL — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
120estimated
Sites
17
Countries
Canada, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-12-29 | actual | When the study began enrolling |
| Primary completion | Aug 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Mar 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2026-01-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-31 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- MASH - Metabolic Dysfunction-Associated Steatohepatitis
Interventions
- Drug: Resmetirom
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFPercent change from baseline in liver fat content (LFC) as assessed by MRI-PDFF at Week 28
measured 28 weeks
Permalink · MDGL's whole pipeline · Catalyst calendar · Every registered study · What changed